Skip to main content
Netherlands News in English

Main navigation

  • Top stories
  • Health
  • Crime
  • Politics
  • Business
  • Tech
  • Culture
  • Sports
  • Weird
  • 1-1-2
Image
1280px-VariousPills
Pills (Photo: MorgueFile / Wikimedia Commons) - Credit: Pills (Photo: MorgueFile / Wikimedia Commons)
Health
HIV
Prep
GGD
Else Hoornenborg
Wednesday, 22 January 2020 - 15:20

Share this article:

PrEP a good preventative against HIV, despite one infection in Dutch test

A GGD study into the HIV inhibitor PrEP showed that the treatment is an effective way to prevent an HIV infection, despite one of the 376 participants in the study contracting the virus, according to the Parool. PrEP, short for Pre-exposure prophylaxis, t is a way for people who do not have HIV, but who are at a high risk of getting the virus, to help prevent HIV infection by taking a pill every day. The pill, marketed under the brand name Truvada, contains the medicines tenofovir and emtricitabine, that are used in combination with other medications.

"We knew before we started the study that the drug was effective, but we didn't know if people would be willing to take the pills faithfully. That turned out to be the case," GGD researcher Else Hoornenborg said to Het Parool.

Worldwide there have been cases of men being infected with HIV despite using PrEP, but in all these cases it involved a viral strain that was already resistant to the treatment. In the single case of infection during the GGD study, could have been stopped by the daily treatment. The researchers did not find out why infection still occurred despite this.

"The risk of HIV is extremely low with PrEP. The main message therefore remains that PrEP offers good prevention. Although it is of course an incredible disappointment for the man who was infected," Hoornenborg said.

The researcher called it extremely important that this treatment become available to anyone who has an increased risk of contracting HIV. "I am thinking of young men who have sex with men, men with a migrant background who have sex with men, and transgender people, because it is difficult to reach them," she said to the newspaper.

Currently, GGD clinics already provide PrEP to certain target groups, and the medication can also be prescribed by many doctors. However it many cases the patient has to pay for it themselves.

"But it would be good if you can also offer it in other ways. For example online, with guidance via the webcam. The guidance must of course be good, but it is worth investigating whether this can be done safely. All this in the hope of removing barriers for men who would otherwise find no way to Prep, and get infected."

More like this

Image
The red AIDS awareness ribbon with a positive HIV blood test on a red background
Number of new HIV infections in Netherlands hasn't declined in five years
Image
HIV awareness ribbon
PrEP care becomes available to everyone at risk of HIV in the Netherlands
Image
HIV awareness ribbon
Amsterdam reports "historic" drop in new HIV infections in 2022
Image
HIV awareness ribbon
Amsterdam to double budget for PrEP trial, giving 400 more access to HIV protection
Make NL Times your top Google source

Follow us:

Latest stories

  • Wasteful Oranje punished as Algeria snatch late victory in World Cup warm-up
  • Dutch State buys medieval ring found with metal detector for €83,150
  • Rotterdam shooting suspect arrested in Spain within days of fleeing
  • Nearly 90% of Dutch dermatologists link TikTok skincare trends to patient skin problems
  • Dogs falling ill, dying after swimming in the IJmeer near Amsterdam & Almere

Top stories

  • Court rules Ye can remain in Netherlands for Arnhem performances this week
  • New A'dam coalition planning parking +tourist tax hike, free public transport for kids
  • European Commission tells Netherlands to stop extra border controls
  • Pregnant woman thrown to ground at Zeist asylum shelter was trying to ask cop a question
  • Senior Dutch virologist, colleague accused of smuggling inactive Mpox into United States

© 2012-2026, NL Times, All rights reserved.

Footer menu

  • Change Privacy Settings
  • Privacy Policy
  • Contact
  • Partner Content